Synthetic cannabis and respiratory depression

Area of Science:

• Toxicology
• Emergency Medicine
• Adolescent Health

Background:

• Synthetic cannabis use, particularly among adolescents, has significantly increased, reaching a 30-year peak in high school seniors.
• The easy accessibility and evolving constituents of synthetic cannabis pose monitoring challenges.
• Despite bans in 40 U.S. states and Schedule I classification, the health effects remain incompletely understood.

Observation:

• Two cases of individuals self-reporting synthetic cannabis use are presented.
• Both cases involved severe respiratory depression following inhalation of synthetic cannabis products.
• Medical intervention, including intubation, was necessary to manage the respiratory compromise.

Findings:

• This is the first reported instance of synthetic cannabis use leading to respiratory depression and the need for intubation.
• The findings indicate a critical, underreported risk associated with synthetic cannabis inhalation.
• The study underscores the potential for severe adverse respiratory events in users.

Implications:

• Highlights the urgent need for further medical research into the respiratory effects of synthetic cannabis.
• Informs public health strategies and clinical awareness regarding the dangers of synthetic cannabis use in adolescents.
• Emphasizes the importance of monitoring and addressing the health consequences of novel psychoactive substances.